Sotatercept

索特西普

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameSotatercept
Drug Alias NameACTRIIA-FcSotatercept-csrkWINREVAIR欣瑞来ACE-011 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionActivin inhibitorsTransforming growth factor beta inhibitors
TargetsActivinsTransforming growth factor beta
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisMyelodysplastic Syndromes +[21] 
Global Approved IndicationsPulmonary Arterial HypertensionHypertension, Pulmonary
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2024/03/26
Country/TerritoryCzechiaBelgiumCanada +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAcceleron Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesPhilipps University MarburgAcceleron Pharma IncMerck Sharp & Dohme Bv +[9] 
Inactive CompaniesMerck Sharp & Dohme CorpNorthwell Health, IncCelgene Corp +[4] 
Active IndicationsPrimary MyelofibrosisMyelodysplastic-Myeloproliferative DiseasesAnemia +[8] 
Inactive IndicationsSolid tumoursMyelodysplastic Syndromesbeta-Thalassemia +[13] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG